Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Anti-retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis.

Goules A, Li J, Antiochos B, Goldman DW, Rosen A, Petri M, Casciola-Rosen L.

ACR Open Rheumatol. 2019 Jun 6;1(5):287-291. doi: 10.1002/acr2.1036. eCollection 2019 Jul.

2.

Myositis Autoantibodies: A Comparison of Results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot.

Mecoli CA, Casal-Dominguez M, Pak K, Pinal-Fernandez I, Albayda J, Tiniakou E, Paik JJ, Zahid U, Danoff SK, Mammen AL, Casciola-Rosen L, Christopher-Stine L.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41088. [Epub ahead of print]

PMID:
31430029
3.

Distinct dermatomyositis populations are detected with different autoantibody assay platforms.

Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L.

Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1048-1051. Epub 2019 Jul 19.

PMID:
31376258
4.

Protective Effect Against Cancer of Antibodies to the Large Subunits of Both RNA Polymerases I and III in Scleroderma.

Shah AA, Laiho M, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2019 Sep;71(9):1571-1579. doi: 10.1002/art.40893. Epub 2019 Aug 1.

PMID:
30888702
5.

Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.

Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L, Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL.

Neurology. 2019 Mar 26;92(13):e1416-e1426. doi: 10.1212/WNL.0000000000007188. Epub 2019 Mar 1.

PMID:
30824556
6.

Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility.

McMahan ZH, Domsic RT, Zhu L, Medsger TA, Casciola-Rosen L, Shah AA.

Arthritis Care Res (Hoboken). 2019 Sep;71(9):1164-1170. doi: 10.1002/acr.23763. Epub 2019 Aug 6.

PMID:
30242973
7.

IFI16 filament formation in salivary epithelial cells shapes the anti-IFI16 immune response in Sjögren's syndrome.

Antiochos B, Matyszewski M, Sohn J, Casciola-Rosen L, Rosen A.

JCI Insight. 2018 Sep 20;3(18). pii: 120179. doi: 10.1172/jci.insight.120179. eCollection 2018 Sep 20.

8.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5. No abstract available.

PMID:
30185415
9.

An update on autoantibodies in scleroderma.

Mecoli CA, Casciola-Rosen L.

Curr Opin Rheumatol. 2018 Nov;30(6):548-553. doi: 10.1097/BOR.0000000000000550. Review.

10.

Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Wolstencroft PW, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2018 Oct 1;154(10):1199-1203. doi: 10.1001/jamadermatol.2018.2549.

11.

Brief Report: Anti-Calponin 3 Autoantibodies: A Newly Identified Specificity in Patients With Sjögren's Syndrome.

Birnbaum J, Hoke A, Lalji A, Calabresi P, Bhargava P, Casciola-Rosen L.

Arthritis Rheumatol. 2018 Oct;70(10):1610-1616. doi: 10.1002/art.40550. Epub 2018 Sep 3.

12.

Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.

Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, Rosen A, Shah AA.

Ann Rheum Dis. 2018 Aug;77(8):1179-1186. doi: 10.1136/annrheumdis-2018-212999. Epub 2018 Apr 20.

13.

Mechanistic and clinical insights at the scleroderma-cancer interface.

Shah AA, Casciola-Rosen L.

J Scleroderma Relat Disord. 2017 Sep-Dec;2(3):153-159. doi: 10.5301/jsrd.5000250. Epub 2017 Oct 5.

14.

Estimating autoantibody signatures to detect autoimmune disease patient subsets.

Wu Z, Casciola-Rosen L, Shah AA, Rosen A, Zeger SL.

Biostatistics. 2019 Jan 1;20(1):30-47. doi: 10.1093/biostatistics/kxx061.

PMID:
29140482
15.

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2018 Jan 1;154(1):44-51. doi: 10.1001/jamadermatol.2017.3758. Erratum in: JAMA Dermatol. 2018 Jan 1;154(1):116.

16.

Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement.

Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L.

Semin Arthritis Rheum. 2018 Feb;47(4):552-556. doi: 10.1016/j.semarthrit.2017.06.004. Epub 2017 Jun 13.

17.

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):71-74. Epub 2017 Jun 19.

18.

Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality.

Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1764-1770. doi: 10.1002/acr.23291.

19.

Reply.

Shah AA, Rosen A, Hummers LK, Wigley FM, Xu G, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Sep;69(9):1915-1916. doi: 10.1002/art.40132. Epub 2017 Jul 11. No abstract available.

20.

Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.

Shah AA, Xu G, Rosen A, Hummers LK, Wigley FM, Elledge SJ, Casciola-Rosen L.

Arthritis Rheumatol. 2017 Jun;69(6):1306-1312. doi: 10.1002/art.40065.

21.

Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.

Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1909-1914. doi: 10.1002/acr.23210. Epub 2017 Nov 2.

22.

More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL.

Rheumatology (Oxford). 2017 May 1;56(5):787-794. doi: 10.1093/rheumatology/kew470.

23.

Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776. doi: 10.1002/acr.23188.

24.

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer.

Xu GJ, Shah AA, Li MZ, Xu Q, Rosen A, Casciola-Rosen L, Elledge SJ.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):E7526-E7534. Epub 2016 Nov 7.

25.

Relationship Between Neuromyelitis Optica Spectrum Disorder and Sjögren's Syndrome: Central Nervous System Extraglandular Disease or Unrelated, Co-Occurring Autoimmunity?

Birnbaum J, Atri NM, Baer AN, Cimbro R, Montagne J, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1069-1075. doi: 10.1002/acr.23107.

26.

Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.

McMahan ZH, Wigley FM, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2017 Jun;69(6):922-926. doi: 10.1002/acr.22978.

27.

Statin-Induced Anti-HMGCR-Associated Myopathy.

Basharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, Lloyd TE, Danoff SK, Casciola-Rosen L, Mammen AL, Christopher-Stine L.

J Am Coll Cardiol. 2016 Jul 12;68(2):234-5. doi: 10.1016/j.jacc.2016.04.037. No abstract available.

28.

Ovoid Palatal Patch in Dermatomyositis: A Novel Finding Associated With Anti-TIF1γ (p155) Antibodies.

Bernet LL, Lewis MA, Rieger KE, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2016 Sep 1;152(9):1049-51. doi: 10.1001/jamadermatol.2016.1429. No abstract available.

29.

Reply.

Baer AN, Petri M, Sohn J, Rosen A, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):454. doi: 10.1002/acr.22917. No abstract available.

30.

Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

McMahan ZH, Cottrell TR, Wigley FM, Antiochos B, Zambidis ET, Park TS, Halushka MK, Gutierrez-Alamillo L, Cimbro R, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 Oct;68(10):2540-9. doi: 10.1002/art.39743.

31.

Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.

Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, Casciola-Rosen L, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Feb;69(2):263-270. doi: 10.1002/acr.22920. Epub 2016 Dec 31.

32.

Autoantigens as Partners in Initiation and Propagation of Autoimmune Rheumatic Diseases.

Rosen A, Casciola-Rosen L.

Annu Rev Immunol. 2016 May 20;34:395-420. doi: 10.1146/annurev-immunol-032414-112205. Epub 2016 Feb 22. Review.

33.

Anti-Interferon-Inducible Protein 16 Antibodies Associate With Digital Gangrene in Patients With Scleroderma.

McMahan ZH, Shah AA, Vaidya D, Wigley FM, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2016 May;68(5):1262-71. doi: 10.1002/art.39558.

34.

Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.

Mammen AL, Casciola-Rosen L, Christopher-Stine L, Lloyd TE, Wagner KR.

Neurol Neuroimmunol Neuroinflamm. 2015 Nov 19;2(6):e172. doi: 10.1212/NXI.0000000000000172. eCollection 2015 Dec.

35.

The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis.

Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL.

J Rheumatol. 2015 Aug;42(8):1448-54.

36.

Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.

Shah AA, Casciola-Rosen L.

Curr Opin Rheumatol. 2015 Nov;27(6):563-70. doi: 10.1097/BOR.0000000000000222. Review.

37.

PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Fiorentino DF, Presby M, Baer AN, Petri M, Rieger KE, Soloski M, Rosen A, Mammen AL, Christopher-Stine L, Casciola-Rosen L.

Ann Rheum Dis. 2016 Jun;75(6):1145-51. doi: 10.1136/annrheumdis-2015-207509. Epub 2015 Aug 7.

38.

Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma.

Shah AA, Montagne J, Oh SY, Wigley FM, Casciola-Rosen L.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S123-6. Epub 2015 Aug 5.

39.

Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome.

Baer AN, Petri M, Sohn J, Rosen A, Casciola-Rosen L.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):254-60. doi: 10.1002/acr.22632.

40.

Spectrum of Muscle Histopathologic Findings in Forty-Two Scleroderma Patients With Weakness.

Paik JJ, Wigley FM, Lloyd TE, Corse AM, Casciola-Rosen L, Shah AA, Boin F, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2015 Oct;67(10):1416-25. doi: 10.1002/acr.22620.

41.

Molecular Subsetting of Interferon Pathways in Sjögren's Syndrome.

Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, Casciola-Rosen L.

Arthritis Rheumatol. 2015 Sep;67(9):2437-46. doi: 10.1002/art.39204.

42.

Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.

Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff SK, Pak K, Casciola-Rosen LA, Mammen AL.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):66-71. doi: 10.1002/acr.22600.

43.

Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.

Shah AA, Hummers LK, Casciola-Rosen L, Visvanathan K, Rosen A, Wigley FM.

Arthritis Rheumatol. 2015 Apr;67(4):1053-61. doi: 10.1002/art.39022.

44.

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.

Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L.

J Am Acad Dermatol. 2015 Mar;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009. Epub 2015 Jan 14.

45.

Review: cancer-induced autoimmunity in the rheumatic diseases.

Shah AA, Casciola-Rosen L, Rosen A.

Arthritis Rheumatol. 2015 Feb;67(2):317-26. doi: 10.1002/art.38928. Review. No abstract available.

46.

Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.

Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF.

Arthritis Care Res (Hoboken). 2015 May;67(5):667-72. doi: 10.1002/acr.22498.

47.

Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.

Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B, Lechtzin N, Mammen AL, Casciola-Rosen L, Christopher-Stine L, Danoff SK.

Respir Med. 2014 Oct;108(10):1542-8. doi: 10.1016/j.rmed.2014.09.003. Epub 2014 Sep 18.

48.

Anti-MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy.

Pau-Charles I, Moreno PJ, Ortiz-Ibáñez K, Lucero MC, Garcia-Herrera A, Espinosa G, Nicolás JM, Castro P, Grau JM, Casciola-Rosen L, Mascaró JM Jr.

J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1097-1102. doi: 10.1111/jdv.12300.

PMID:
25243267
49.

Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.

Mohassel P, Rosen P, Casciola-Rosen L, Pak K, Mammen AL.

Arthritis Rheumatol. 2015 Jan;67(1):266-72. doi: 10.1002/art.38863.

50.

Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D.

JAMA Dermatol. 2014 Jul;150(7):724-9. doi: 10.1001/jamadermatol.2013.10416.

Supplemental Content

Loading ...
Support Center